Exudative Age-related Macular Degeneration
Conditions
Keywords
optical coherence tomography angiography, optical coherence tomography angiography angiography, bevacizumab, vascular endothelial growth factor antagonists, intravitreal injection
Brief summary
This study evaluates the retinal and vascular features in patients with macular degeneration under the effects of Bevacizumab intravitreal injections using optical coherence tomography and optical coherence tomography angiography.
Detailed description
Bevacizumab is a vascular endothelial growth factor antagonist represent an efficacy treatment for exudative age-related macular degeneration acting on vascular hyperpermeability. The optical coherence tomography and optical coherence tomography angiography represent novel and non-invasive diagnostic techniques that allow a detailed and quantitative analysis of retinal and vascular features. The study evaluates the changes in optical coherence tomography and optical coherence tomography angiography parameters at baseline and after three monthly injections of Bevacizumab in exudative AMD.
Interventions
DRUGBevacizumab Injection
Three monthly intravitreal injections of bevacizumab (1.25 mg/0.05 mL)
Sponsors
Federico II University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
50 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* age older than 50 years, diagnosis of exudative age-related macular degeneration, treatment-naïve with Bevacizumab for exudative age-related macular degeneration.
Exclusion criteria
* age younger than 50 years, diagnosis of exudative macular degeneration due to other causes, previous treatments before Bevacizumab for exudative age-related macular degeneration.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Study of retinal structural features in exudative age-related macular degeneration after intravitreal injections of Bevacizumab | three months | The effectiveness of Bevacizumab injections for treating exudative age-related macular degeneration using optical coherence tomography. The parameters analyzed by optical coherence tomography: Central Macular Thickness and Subfoveal Choroidal thickness (microns). |
| Study of retinal vascular features in exudative age-related macular degeneration after intravitreal injections of Bevacizumab | three months | The effectiveness of Bevacizumab injections for treating exudative age-related macular degeneration using optical coherence tomography angiography. The parameters analyzed by optical coherence tomography angiography were: retinal and choriocapillaris vessel density (%). |
Countries
Italy
Outcome results
None listed